Diagnosing Fibrosis in ARDS

Clinical Timeline and Recognition

The exudative phase of ARDS typically occurs within the first 5 days, characterized by interstitial swelling, proteinaceous alveolar edema, and hyaline membranes, according to the European Society of Intensive Care Medicine 1
The fibroproliferative phase of ARDS typically begins around days 6-10, characterized by mononuclear cell infiltration, fibroblast proliferation, and collagen deposition, as stated by the European Society of Intensive Care Medicine 1
The fibrotic phase of ARDS occurs after 10 days, characterized by established fibrosis with widened interstitial spaces, as described by the European Society of Intensive Care Medicine 1

Additional biomarkers under investigation for ARDS diagnosis include IL-8, procollagen peptide in airspace lavage, and von Willebrand factor antigen, although these lack consistent validation, according to the European Society of Intensive Care Medicine 2

Standard chest X-rays are poor predictors of fibrosis severity and clinical outcome in ARDS patients, as stated by the European Society of Intensive Care Medicine 1 and the European Respiratory Society 3

Patients developing fibrosis have significantly worse outcomes, including higher mortality, prolonged ventilator dependence, and impaired long-term health-related quality of life, according to the European Society of Intensive Care Medicine 2
Liver failure in association with ARDS and fibrosis carries a particularly poor prognosis, as stated by the European Society of Intensive Care Medicine 2

The European Respiratory Society emphasizes the need to identify patients with unresolved ARDS who have fibroproliferation versus nosocomial infection or persistent primary cause 4
The European Respiratory Society prioritizes testing treatments such as corticosteroids or anti-fibrotic agents in clinical trials specifically for patients with documented fibroproliferation 4